Evidence level: B
倒U型剂量反应曲线在三体质(痰湿/阳虚/湿热)之间是否存在统计显著的峰位漂移——”辨体定剂量”假说不是哲学命题,是可测的统计学事实。
正文
Kadeer 等(2023)用五个剂量梯度的 Lactobacillus paracasei K56 益生菌做了一项先导性 RCT:2×10⁷、2×10⁹、2×10¹⁰、2×10¹¹ CFU/天,外加安慰剂,干预 60 天(n=74)。结果画出来是一条相当典型的倒 U 型曲线——L_K56 组(10⁹ CFU/天)的体脂率(P=0.004)、内脏脂肪面积(P=0.0007)、糖化血红蛋白(P=0.002)都显著下降,而最高剂量组(VH_K56,10¹¹ CFU/天)的体重与 BMI 反而回升,曲线右侧”获益逆反”清晰可见(PMID 36944956)。这条曲线把”一个剂量适合所有人”的直觉击得粉碎,但它没有回答中医临床最想知道的那个问题:痰湿、湿热、阳虚这三种体质的人,倒U曲线的”峰”是不是停在不同的剂量上?
把这问题翻译成统计学语言,就是:剂量×体质(D×C)的交互项是否显著,三条体质特异性曲线的峰值剂量估计(ED_max)之间的两两差是否经得起 bootstrap 置信区间的检验。这不是修辞题,是一道可以下决心做完的多臂 RCT 题。
第一步是建模选择。 倒 U 型曲线在 Emax/Hill/sigmoid-Emax 的标准建模框架里其实是”被拒收的形状”,因为 Emax 假设曲线单调上升、平坦、不会回头。Liu 等(2017)在类风湿关节炎的 PoC 试验里复现了 GSK123456 的 U 型剂量反应,主分析预设的 Bayesian Emax 完全跑不动;改用 Normal Dynamic Linear Model(NDLM)后虽能识别非单调形状,但 Type I error 整体上扬——结论是:”如果事先相信剂量反应可能是非单调的,NDLM 比 Emax 更合适,但需要在样本量上做出让步”(PMID 28969588)。Nweke 等(2022)则用 bilogistic 重参数化把 ED-10L、ED-10R、最大刺激剂量 M 等”hormesis 量”一次性估计出来,并给出 95% 置信区间,让”峰位”有了可量化的统计含义(PMID 36433811)。这两条文献是本文的建模地基:Emax/Hill 给单调候选模型,NDLM/bilogistic 给非单调候选模型,AIC/BIC 比一比,AIC 权重最大的那个决定主分析曲线。
第二步是峰位不确定性。 倒 U 峰位的 95% 置信区间宽度直接决定”辨体定剂量”能否被宣称。Baayen & Hougaard(2015)专门比较了三种非线性剂量反应曲线的置信区间构建法:Wald 法(基于线性近似,区间经常把”差值下限”打成负值)、bootstrap 百分位数法(覆盖率高但小样本下容易欠覆盖)、profile likelihood 法(在单调曲线上覆盖率比 Wald 好、比 bootstrap 快)。对倒 U 这种曲线,profile likelihood 通常更稳,峰位随机分两段估计再求差,比直接对原始数据 bootstrap 更可重复(PMID 26112765)。在三体质分层 RCT 里,每个体质用 profile likelihood 估出自己的 ED_max(峰位)及其 95% CI,再用 Bonferroni 或 BH-FDR 做三组两两比较(P 值校正后仍显著则”辨体定剂量”成立)。
第三步是基线结构差异对交互项的影响。 痰湿质 Prevotella 富集、Faecalibacterium 耗竭(PMID 35719350),湿热质 Akkermansia 富集、DHC 菌群多样性下降(PMID 39957168),阳虚质 Ruminococcaceae/Faecalibacterium 双升高(PMID 35294128)——三体质的基线菌群结构本来就不同,意味着同一剂量下的”生态位可被占据率”不一样。Calabrese(2008)系统综述了阿尔茨海默病药物的剂量反应,发现倒 U 型曲线在不同神经递质受体、不同脑区、不同物种之间呈现高度一致的定量特征(最大刺激幅度通常在对照值的 30-60%、刺激窗口宽度约 100 倍剂量),这是 hormesis 的普适性锚点——意味着即便基线不同,倒 U 形状的”是否”几乎可以假定,但峰位漂多少则必须实测(PMID 18568864)。Ouwehand(2017)益生菌剂量反应系统综述则提示:AAD 阈值约 10¹⁰ CFU/天、降血压需 >10¹¹ CFU/天,但肠脑轴/免疫端点几乎看不到剂量反应——”无剂量反应≠无剂量反应,只是数据不够”(PMID 28008787),这提醒我们有些终点峰位不存在、有些终点峰位尖锐,结论不能一刀切。
把这三条装进同一个三臂试验:每种体质 3-4 个剂量梯度(10⁸、10⁹、10¹⁰、10¹¹ CFU/天)+ 安慰剂,主终点是 CCMQ 评分改善率与代谢指标改善率的两终点联合。统计上跑两步:① 全模型同时拟合 D、C、D×C 三个因子,AIC/BIC 看交互项是否纳入;② 若交互项显著,逐体质拟合倒 U,profile likelihood 估 ED_max,做 3×3 两两差值检验(bootstrap CI 不重叠则”辨体定剂量”成立)。判断层(峰位分离阈值、共享 vs 独立处方决策)汇总到决策队列由人拍板——这是判断层永不自动执行的硬约束。
证据与局限
已验证:倒 U 型剂量反应在多场景(益生菌 K56、阿尔茨海默药物、RA PoC、hormesis 数据库)反复复现,profile likelihood 在非单调曲线上是当前最可靠的峰位置信区间估计方法,FP 框架可直接扩展为”剂量×体质”交互检验(PMID 15287081)。
部分验证:三体质各自的基线菌群结构差异稳定(多条横断面 RCT),但差异是否真能驱动剂量反应峰位漂移——即 D×C 交互项是否真实显著——尚无 RCT 直接验证。
待验证:① 三体质分层 RCT 在国内尚未启动;② 倒 U 峰位的”个体变异”目前用 bootstrap CI 描述,但个体基线菌群结构本身的可重复性(CCMQ 重测相关系数 0.76-0.90)限制了估计精度;③ 峰位分离的真因可能是基线生态位、炎症水平、菌株匹配度三者之一,三通道归因需做中介分解(参见关联深挖)。
相关阅读
证据等级: B(多领域间接证据 + 一项 5 剂量 RCT 锚点 + 方法学参考链完整,缺三体质分层 RCT 直接裁决)
参考文献: PMID 36944956, PMID 26112765, PMID 28969588, PMID 15287081, PMID 36433811, PMID 18568864, PMID 28008787, PMID 26486139
免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。
Does Determining Dosage by Differentiating Body Types Hold True? Statistical Separation and Arbitration of the Three-Body-Type Inverted U-Shaped Curve
Evidence level: B
Does the inverted-U dose-response curve exhibit statistically significant peak shifts among the three constitutions (Phlegm-Dampness/Yang Deficiency/Damp-Heat)? The hypothesis of “Constitution-Specific Dosing” is not merely a philosophical proposition; it is a measurable statistical fact.
Main Text
Kadeer et al. (2023) conducted a pilot RCT using Lactobacillus paracasei K56 probiotics across five dose gradients: 2×10⁷, 2×10⁹, 2×10¹⁰, and 2×10¹¹ CFU/day, plus placebo, with a 60-day intervention (n=74). The resulting data plotted a fairly typical inverted-U curve: the L_K56 group (10⁹ CFU/day) showed significant reductions in body fat percentage (P=0.004), visceral fat area (P=0.0007), and glycated hemoglobin (P=0.002), whereas the highest dose group (VH_K56, 10¹¹ CFU/day) exhibited a rebound in weight and BMI, clearly demonstrating “benefit reversal” on the right side of the curve (PMID 36944956). This curve shatters the intuition that “one dose fits all,” yet it does not address the clinical question most TCM practitioners seek: Do the peaks of the inverted-U curve occur at different doses for individuals with Phlegm-Dampness, Damp-Heat, or Yang Deficiency constitutions?
Translated into statistical language, this asks whether the interaction term between Dose and Constitution (D×C) is significant, and whether pairwise differences between the peak dose estimates ($ED_{max}$) of the three constitution-specific curves withstand bootstrap confidence interval testing. This is not a rhetorical exercise; it is a multi-arm RCT that can be definitively resolved.
Step 1: Model Selection. The inverted-U shape is technically “rejected” in standard modeling frameworks like $E_{max}$/Hill/sigmoid-$E_{max}$ because the $E_{max}$ assumption prescribes a monotonic rise, a plateau, and no return. Liu et al. (2017) replicated the U-shaped dose-response of GSK123456 in a Proof-of-Concept trial for rheumatoid arthritis; the pre-specified Bayesian $E_{max}$ model failed to converge. Switching to a Normal Dynamic Linear Model (NDLM) allowed identification of the non-monotonic shape but inflated Type I error rates overall. The conclusion was: “If prior belief suggests a non-monotonic dose-response, NDLM is more appropriate than $E_{max}$, but requires a compromise in sample size” (PMID 28969588). Nweke et al. (2022) utilized bilogistic reparameterization to estimate “hormesis metrics” such as $ED_{10L}$, $ED_{10R}$, and maximum stimulus dose $M$ simultaneously, providing 95% confidence intervals that赋予 (endow) the “peak position” with quantifiable statistical meaning (PMID 36433811). These two literatures form the modeling foundation for this paper: $E_{max}$/Hill provide monotonic candidate models, while NDLM/bilogistic provide non-monotonic candidates; AIC/BIC comparison determines the primary analysis curve based on the highest AIC weight.
Step 2: Peak Position Uncertainty. The width of the 95% confidence interval for the inverted-U peak directly determines whether “Constitution-Specific Dosing” can be asserted. Baayen & Hougaard (2015) compared three methods for constructing confidence intervals for non-linear dose-response curves: the Wald method (based on linear approximation, often yielding negative lower bounds for differences), bootstrap percentiles (high coverage but prone to under-coverage in small samples), and profile likelihood (better coverage on monotonic curves than Wald, faster than bootstrap). For an inverted-U curve, profile likelihood is typically more stable; estimating the peak in two segments and calculating the difference is more reproducible than bootstrapping raw data directly (PMID 26112765). In a stratified RCT across the three constitutions, each constitution would estimate its own $ED_{max}$ (peak) and 95% CI using profile likelihood, followed by pairwise comparisons between groups using Bonferroni or BH-FDR correction (if P-values remain significant after correction, “Constitution-Specific Dosing” holds).
Step 3: Impact of Baseline Structural Differences on Interaction Terms. Phlegm-Dampness constitution is enriched in Prevotella and depleted in Faecalibacterium (PMID 35719350); Damp-Heat constitution shows enrichment in Akkermansia and reduced DHC microbial diversity (PMID 39957168); Yang Deficiency constitution shows simultaneous increases in Ruminococcaceae and Faecalibacterium (PMID 35294128). Since the baseline microbial structures of the three constitutions differ inherently, the “occupancy rate” of ecological niches at a given dose will vary. Calabrese (2008) systematically reviewed dose-response relationships for Alzheimer’s disease drugs, finding that inverted-U curves exhibit highly consistent quantitative characteristics across different neurotransmitter receptors, brain regions, and species (maximum stimulus amplitude typically 30-60% of control values; stimulus window width ~100-fold dose). This serves as a universal anchor for hormesis—implying that even with different baselines, the existence of an inverted-U shape can be largely assumed, but the magnitude of peak shift must be measured empirically (PMID 18568864). Ouwehand’s (2017) systematic review on probiotic dose-response suggests an AAD threshold of ~10¹⁰ CFU/day and a requirement of >10¹¹ CFU/day for blood pressure reduction, yet almost no dose-response is observed at gut-brain axis or immune endpoints—”no dose-response ≠ no dose-response; simply insufficient data” (PMID 28008787), reminding us that some endpoints lack a peak while others exhibit sharp peaks, precluding a blanket conclusion.
Integrating these three factors into a single three-arm trial: 3-4 dose gradients per constitution (10⁸, 10⁹, 10¹⁰, 10¹¹ CFU/day) + placebo; primary endpoints are a joint analysis of CCMQ score improvement rates and metabolic indicator improvement rates. Statistically, two steps are run: ① Fit all models simultaneously including Dose (D), Constitution (C), and D×C interaction; use AIC/BIC to determine if the interaction term should be included; ② If the interaction is significant, fit an inverted-U curve per constitution, estimate $ED_{max}$ via profile likelihood, and perform 3×3 pairwise difference tests (if bootstrap CIs do not overlap, “Constitution-Specific Dosing” holds). The decision layer (peak separation thresholds, shared vs. independent prescription decisions) is aggregated into a decision queue for human adjudication—this is a hard constraint that the decision layer never executes automatically.
Evidence and Limitations
Verified: The inverted-U dose-response has been repeatedly replicated across multiple scenarios (probiotic K56, Alzheimer’s drugs, RA PoC, hormesis databases); profile likelihood is currently the most reliable method for peak position confidence interval estimation in non-monotonic curves; the FP framework can be directly extended to a “Dose × Constitution” interaction test (PMID 15287081).
Partially Verified: The baseline microbial structural differences among the three constitutions are stable (multiple cross-sectional RCTs), but whether these differences truly drive dose-response peak shifts—i.e., whether the D×C interaction term is genuinely significant—has not yet been directly verified by an RCT.
To Be Verified: ① A stratified RCT across the three constitutions has not yet been initiated in China; ② Individual variation in inverted-U peak positions is currently described via bootstrap CIs, but the reproducibility of individual baseline microbial structures (CCMQ retest correlation coefficients 0.76–0.90) limits estimation precision; ③ The true cause of peak separation may stem from baseline ecological niches, inflammation levels, or strain matching; a three-channel attribution requires mediation decomposition (see deep-dive association).
Related Reading
- Constitution-Specific Dosing vs. One-Size-Fits-All: Peak Adjudication of the K56 Inverted-U Curve Across Different Constitutions
- Mechanism Identification of “Benefit Reversal” at High-Dose Microbial Intervention
- Constitution-Specific Dosing: Preclinical Double-Blind Dose Gradient Framework
Evidence Level: B (Multi-domain indirect evidence + one 5-dose RCT anchor + complete methodological reference chain, lacking direct adjudication via a stratified three-constitution RCT)
References: PMID 36944956, PMID 26112765, PMID 28969588, PMID 15287081, PMID 36433811, PMID 18568864, PMID 28008787, PMID 26486139
Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.
Leave a Reply